FDA Expands Approval of Fulvestrant for Advanced Breast Cancer September 23, 2017October 3, 2017BioSky Comment On August 28, the Food and Drug Administration (FDA) expanded its approval of the estrogen-blocking drug fulvestrant (Faslodex®) for some women with advanced breast cancer. The new
